Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 1049 Indian stocks· EOD 2026-07-29

Anupam Rasayan India Ltd

ANURASNSEChemicals
₹1,214.4
-4.00 (-0.33%)
Sell

Financial trend (54/100) does the heavy lifting; valuation (16/100) is the drag.

ExpensiveOvervalued
The bottom line

Our blended model reads Anupam Rasayan India Ltd as a Sell at 33/100. On 83.3x trailing earnings it sits pricier than the Chemicals median of about 41.0x. The price is about 12% below its 52-week high of ₹1,376 and 14% above the low of ₹1,064.7. Financial health scores 96/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,065 implies about 12% downside across 6 analysts. It clears 3 of 13 investability checks, with durability 40, valuation 24 and momentum 26 on our 0–100 scales.

Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹907.05down 25.31%
Overvalued by 25%
Price ₹1,214.4Range ₹607.2₹1,281.1
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹725.64.

Analyst views

6 analysts3 buy · 0 hold · 4 sell
12-month consensus target₹1,065down 12.30%

1-year price

EOD · 2026-07-29
1D
down 0.33%
1W
down 2.94%
1M
down 3.95%
3M
down 9.63%
6M
down 1.28%
1Y

52-week range

-11.74% from the 52-week high.

Trend check
Below 50-DMA₹1,285Below 200-DMA₹1,260

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Sell33
A
Financial health 96/100
Altman Z 4.85 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Our scores

Durability40
Valuation24
Momentum26

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 3 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Fail: ROE above 15%: 5.8%
  • Pass: Low debt (D/E < 0.5): 0.40x
  • Fail: Positive free cash flow
  • Pass: Revenue growth > 10%: 28%
  • Fail: Earnings growing: -8%
  • Fail: Net margin ≥ 10%: 7.2%
  • Fail: Current ratio > 1.5: 1.43
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Fail: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 4.85
  • Fail: Piotroski ≥ 7: 4/9

Quarterly results

Revenue · 1Q2026
₹371 Cr
Net profit
₹43 Cr
Margin
12%
2Q2025
3Q2025
4Q2025
1Q2026
Revenue Net profitLatest revenue QoQ -28%

Annual financials

Revenue · 2026
₹2,365 Cr
Net profit
₹170 Cr
Margin
7%
2023
2024
2025
2026
Revenue Net profitLatest revenue YoY +164%

Shareholding

  • Promoter85.0%
  • Institutions0.5%
  • Public & other14.5%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹14,585 Cr
P/E ratio
83.3
P/B ratio
4.37
EPS (TTM)
₹15.38
ROE
5.8%
Debt / Equity
0.40x
Profit margin
7.2%
Free cash flow
₹-481 Cr
52-week high
₹1,376
-11.74% from high
52-week low
₹1,064.7
Dividend yield
0.1%
Beta
0.11
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Financially solid — Altman Z 4.85.

Opportunities

  • Revenue growing (28% YoY).

Bear case

Weaknesses

  • Low return on equity (5.8%).
  • Price below its 200-day moving average (downtrend).

Threats

  • Earnings contracting year on year.
  • Rich valuation versus sector peers.
  • Trades ~25% above our estimated fair value.

About Anupam Rasayan India Ltd

Anupam Rasayan India manufactures custom synthesis specialty chemicals across life science and other segments, serving agrochemical, pharmaceutical, and related industries. The company operates manufacturing facilities in India, Europe, Japan, Singapore, China, and North America, producing agro intermediates, agro active ingredients, anti-bacterial compounds, and ultraviolet protection intermediates.

Anupam Rasayan India Ltd — frequently asked questions

Is Anupam Rasayan India Ltd a buy, hold or sell?

StocksWizard currently rates Anupam Rasayan India Ltd (ANURAS) a Sell, based on a blended score of 33/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Anupam Rasayan India Ltd's fair value?

Our blended DCF and relative-valuation model estimates Anupam Rasayan India Ltd's fair value at about ₹907.05, versus a current price of ₹1,214.4 — roughly 25% downside. On that basis the stock looks overvalued by 25%.

Is Anupam Rasayan India Ltd financially healthy?

Anupam Rasayan India Ltd scores 96/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.

How has Anupam Rasayan India Ltd's share price performed?

Anupam Rasayan India Ltd is down 10% over three months, and last traded at ₹1,214.4. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.